Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AddLife | Stoccolma | Salute | Ricerca medica e biotecnologica | 19,85 Mrd SEK | 168,3x | -2,41 | 163,20 SEK | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,5% Rialzo | Fai l’upgrade a Pro+ | |
BioArctic | Stoccolma | Salute | Ricerca medica e biotecnologica | 14,50 Mrd SEK | -164,6x | 1,23 | 164,40 SEK | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioinvent | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,90 Mrd SEK | -7,5x | 0,3 | 43,95 SEK | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hansa Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,77 Mrd SEK | -2,8x | -0,54 | 40,98 SEK | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Devyser Diagnostics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,18 Mrd SEK | -32,4x | -3,7 | 131 SEK | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 15,3% Rialzo | Fai l’upgrade a Pro+ | |
Vicore Pharma Holding AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,98 Mrd SEK | -4,7x | -0,21 | 8,47 SEK | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
XSpray Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,70 Mrd SEK | -7,3x | -0,72 | 50,50 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cereno Scientific | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,66 Mrd SEK | -20,7x | 0,27 | 5,86 SEK | -4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nykode Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,64 Mrd SEK | -4,5x | 13,98 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Nanoform Finland Plc | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,62 Mrd SEK | -6,7x | -10,29 | 19 SEK | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Diamyd Medical | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,37 Mrd SEK | -8,5x | 1,09 | 13,70 SEK | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Egetis Therapeutics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,34 Mrd SEK | -4x | -0,6 | 4,60 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alligator Bioscience | Stoccolma | Salute | Ricerca medica e biotecnologica | 961,19 Mln SEK | -3,6x | -0,07 | 1,28 SEK | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Intellego Technologies AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 741,47 Mln SEK | 7,3x | 0,05 | 26 SEK | -2,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hamlet Pharma AB | Spotlight | Salute | Ricerca medica e biotecnologica | 736,48 Mln SEK | -16,4x | 0,48 | 4,10 SEK | -6,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Promimic AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 643,68 Mln SEK | -61,8x | -4,44 | 34,80 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cantargia AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 587,80 Mln SEK | -2,5x | -0,09 | 3,20 SEK | -4,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Saniona AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 522,82 Mln SEK | -5x | 0,08 | 4,68 SEK | 3,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 32,2% Rialzo | Fai l’upgrade a Pro+ | |
Oncopeptides | Stoccolma | Salute | Ricerca medica e biotecnologica | 449,74 Mln SEK | -1,7x | -0,03 | 2,09 SEK | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Mendus AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 415,42 Mln SEK | -2,4x | -0,04 | 8,25 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Initiator Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 403,56 Mln SEK | -21x | -0,37 | 7,20 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
SynAct Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 369,60 Mln SEK | -1,8x | -0,45 | 8,83 SEK | -1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curasight AS | Spotlight | Salute | Ricerca medica e biotecnologica | 345,81 Mln SEK | -7x | 0,25 | 16,17 SEK | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Peptonic Medical | Spotlight | Salute | Ricerca medica e biotecnologica | 345,33 Mln SEK | -0,2x | -0,02 | 0,006 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medivir | Stoccolma | Salute | Ricerca medica e biotecnologica | 314,07 Mln SEK | -0,2 | 2,80 SEK | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Alzinova | Stoccolma | Salute | Ricerca medica e biotecnologica | 312,08 Mln SEK | -8,4x | -1,51 | 3,52 SEK | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Guard Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 307,37 Mln SEK | -3,2x | -0,07 | 25 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Xintela | Stoccolma | Salute | Ricerca medica e biotecnologica | 280,97 Mln SEK | -6,1x | -0,1 | 0,49 SEK | 4,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Xbrane Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 275,31 Mln SEK | -0,2x | -0,01 | 0,17 SEK | -10% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Annexin Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 271,82 Mln SEK | -2,6x | -0,25 | 0,53 SEK | 3,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |